What is Enteric Hyperoxaluria?
313 بار بازدید -
2 سال پیش
-
Kyle Wood, MD, Associate Professor
Kyle Wood, MD, Associate Professor of Urology, University of Alabama at Birmingham, gives an overview of enteric hyperoxaluria.
As Dr. Wood explains, enteric hyperoxaluria is a rare metabolic disorder characterized by excessive absorption of dietary oxalate. It is often caused by Roux-en-Y gastric bypass surgery or an underlying chronic gastrointestinal disorder associated with malabsorption. Enteric hyperoxaluria differs from primary hyperoxaluria, a related kidney disorder, as patients with primary hyperoxaluria produce an excess of oxalate whereas patients with enteric hyperoxaluria absorb an excess of oxalate from their diet. In both of these conditions, elevated oxalate in the blood leads to oxalate crystal formation in the kidney, causing kidney stones, excruciating pain, and progressive renal damage.
There is currently no FDA-approved treatment for enteric hyperoxaluria. Current management may include increased fluid intake, calcium supplements, and dietary restrictions. SYNB8802, an orally administered, non-systemically absorbed drug candidate, is currently under investigation as a treatment of enteric hyperoxaluria and results from a phase 1b study of this drug were positive.\
To learn more about enteric hyperoxaluria and other rare metabolic disorders, visit checkrare.com/diseases/metabolic-disorders/
As Dr. Wood explains, enteric hyperoxaluria is a rare metabolic disorder characterized by excessive absorption of dietary oxalate. It is often caused by Roux-en-Y gastric bypass surgery or an underlying chronic gastrointestinal disorder associated with malabsorption. Enteric hyperoxaluria differs from primary hyperoxaluria, a related kidney disorder, as patients with primary hyperoxaluria produce an excess of oxalate whereas patients with enteric hyperoxaluria absorb an excess of oxalate from their diet. In both of these conditions, elevated oxalate in the blood leads to oxalate crystal formation in the kidney, causing kidney stones, excruciating pain, and progressive renal damage.
There is currently no FDA-approved treatment for enteric hyperoxaluria. Current management may include increased fluid intake, calcium supplements, and dietary restrictions. SYNB8802, an orally administered, non-systemically absorbed drug candidate, is currently under investigation as a treatment of enteric hyperoxaluria and results from a phase 1b study of this drug were positive.\
To learn more about enteric hyperoxaluria and other rare metabolic disorders, visit checkrare.com/diseases/metabolic-disorders/
2 سال پیش
در تاریخ 1401/12/17 منتشر شده
است.
313
بـار بازدید شده